NCT00690443View on ClinicalTrials.gov

Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Hypercholesterolemia
Interventions
DRUG

Atorvastatin

atorvastatin 20 mg tablets, daily dosing, for 8 weeks.

DRUG

AEGR-733

2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks

Trial Locations (5)

33781

Linda Murray, DO - Radiant Research, Pinellas Park

44260

Dennis McCluskey, MD - Radiant Research, Mogadore

55435

Sheila Rodstein, MD, Edina

75231

Michele Reynolds, MD, Dallas

78229

William Jennings, MD - Radiant Research, San Antonio

Sponsors
All Listed Sponsors
lead

Aegerion Pharmaceuticals, Inc.

INDUSTRY

NCT00690443 - Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia | Biotech Hunter | Biotech Hunter